Investment continues in cell and gene sector, despite disruptions

April 25, 2022

Investment in the cell and gene therapy sector remains robust, despite the disruptions over the last several years due to the COVID-19 pandemic. That's one of the take-home messages from this week's Cell & Gene Meeting on the Mediterranean, according to ScienceBoard Vice President of Digital Media Sales Walt Schoenborn and reporter Melisande Rouger, who were on site in Barcelona, Spain.

A major emphasis has been made on seeing things from the patient perspective, including in the development of clinical trials for new cell and gene therapy treatments. What's more, partnership activity between vendors has continued at a robust pace. Still, major differences remain between the U.S. and Europe.

Click on the video below for more details from this year's meeting, which was sponsored by the Alliance for Regenerative Medicine.


Regional government steps in to boost gene therapy manufacturing in Spain
BARCELONA, SPAIN -- Early cooperation between the government of the Basque region in northern Spain and companies can help boost manufacturing of gene...
Meeting on the Med opens with new data and eyes on the money
BARCELONA, SPAIN -- The Cell & Gene Meeting on the Med conference kicked off on April 20 as speakers assessed the current state of the cell and gene therapy...
Catching up with the Alliance for Regenerative Medicine at Cell & Gene Meeting on the Mesa
CARLSBAD, CA - What's going on at this week's Cell & Gene Meeting on the Mesa? ScienceBoard.net spoke with Stephen Majors, director of public...
Meeting on the Mesa ramps up rules on COVID-19 vaccination, testing
The Alliance for Regenerative Medicine has implemented new rules for its Cell & Gene Meeting on the Mesa, which is scheduled for October 12-14, 2021,...

Copyright © 2022 scienceboard.net

Last Updated mf 4/25/2022 4:07:35 PM